AEZS 108 enters Phase II clinical trial in men with taxane-refractory mCRPC

According to a company media release, Aeterna Zentaris has initiated the Phase II component of the Phase I/II trial of AEZS 108 in the treatment of men with castration- and taxane-resistant prostate cancer. … READ MORE …

Taregted therapy and companion diagnostic: the AEZS-108 story

Here’s a clear signal that prostate cancer is entering the world of targeted therapeutics associated with specific companion diagnostics: the Canadian company Aeterna Zentaris has announced a partnership to develop a companion diagnostic to identify patients likely to respond to their targeted therapy AEZS-108. … READ MORE …

If AEZS-108 works in endometrial cancer … will it work in prostate cancer too?

Earlier this week the Canadian biotech company Aeterna Zentaris announced results from a Phase II trial of its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer. This may have implications for the potential of AEZS-108 in prostate cancer too. … READ MORE …